Keeping you updated on the latest Medicare and Part D news

EpiPen designation as a generic medication reinvigorates criticism of Mylan’s practices

Leave a comment

A new development in the ongoing EpiPen controversy – drug maker Mylan has been telling the federal government the product is a generic. This classification likely resulted in individual state Medicaid programs paying more for the product, since the company provides smaller discounts to states for generic drugs. The generic designation seems to predate Mylan’s ownership of the EpiPen product though the company objected to new government rules which will require requesting a waiver instead of reclassifying some older products as brand name. Much has been made recently of Mylan’s repeated increase of the price of the EpiPen product and the recent announcement that it will offer a generic version of the product at a reduced cost in an attempt to mollify critics.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s